Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy.
Sixty-three patients with Parkinson's disease who failed bromocriptine therapy for various reasons were treated in an open-label trial of pergolide. The data were evaluated in a retrospective manner. Forty-six percent had a good response and tolerated the pergolide. A comparison of the outcomes regarding response and toxicity revealed that bromocriptine and pergolide act differently in individual patients. A trial of pergolide in Parkinsonian patients failing bromocriptine therapy may be therapeutically useful.
Factor
S A
SA
University of Miami School of Medicine, Department of Neurology, Florida 33101.
Sanchez-Ramos
J R
JR
Weiner
W J
WJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000009:adverse effects / Q000627:therapeutic use*
D010479:Pergolide; D001971:Bromocriptine